Virbac Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Virbac ha aumentado sus beneficios a una tasa media anual de 20.8%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 15.3% anual. Los ingresos han ido creciendo a una tasa media de 7.9% al año. La rentabilidad financiera de Virbac es de 13.3%, y sus márgenes netos son de 9.7%.

Información clave

20.8%

Tasa de crecimiento de los beneficios

20.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	16.3%
Tasa de crecimiento de los ingresos	7.9%
Rentabilidad financiera	13.3%
Margen neto	9.7%
Próxima actualización de resultados	13 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results

Mar 22

Virbac SA's (EPA:VIRP) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 05

Does Virbac's (EPA:VIRP) Share Price Gain of 96% Match Its Business Performance?

Dec 18

Estimating The Fair Value Of Virbac SA (EPA:VIRP)

Dec 01

Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Nov 18

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Virbac. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

ENXTPA:VIRP Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	1,247	121	573
30 Sep 23	1,229	120	570
30 Jun 23	1,210	119	568
31 Mar 23	1,213	121	563
31 Dec 22	1,216	122	557
30 Sep 22	1,184	120	535
30 Jun 22	1,151	119	513
31 Mar 22	1,107	116	500
31 Dec 21	1,064	113	487
30 Sep 21	1,025	137	473
30 Jun 21	985	161	459
31 Mar 21	960	148	449
31 Dec 20	934	136	439
30 Sep 20	944	104	444
30 Jun 20	953	72	448
31 Mar 20	946	62	451
31 Dec 19	938	52	454
30 Sep 19	921	43	449
30 Jun 19	903	34	445
31 Mar 19	886	27	446
31 Dec 18	869	20	446
30 Sep 18	862	8	442
30 Jun 18	854	-4	438
31 Mar 18	858	-3	440
31 Dec 17	862	-3	442
30 Sep 17	871	16	444
30 Jun 17	879	35	446
31 Mar 17	876	35	449
31 Dec 16	872	35	452
30 Sep 16	861	30	459
30 Jun 16	850	26	466
31 Mar 16	851	18	463
31 Dec 15	853	9	460
30 Sep 15	846	21	441
30 Jun 15	839	32	421
31 Mar 15	806	48	398
31 Dec 14	773	64	375
30 Sep 14	752	60	366
30 Jun 14	730	56	357
31 Mar 14	733	58	356
31 Dec 13	736	61	355
30 Sep 13	727	61	356
30 Jun 13	718	61	356

Ingresos de calidad: VIRP tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(9.7%) de VIRP son inferiores a los del año pasado (10%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lVIRP han crecido significativamente en un 20.8% al año.

Acelerando crecimiento: VIRP ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: VIRP tuvo un crecimiento negativo de los beneficios (-0.5%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (-0.5%).

Virbac Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: EPS: €14.40 (vs €14.43 in FY 2022)

Full year 2023 earnings: EPS misses analyst expectations

Virbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024

First half 2023 earnings released: EPS: €8.86 (vs €9.18 in 1H 2022)

Full year 2022 earnings released: EPS: €14.44 (vs €13.40 in FY 2021)

Virbac SA to Report First Half, 2023 Results on Sep 14, 2023

Recent updates

Full year 2023 earnings released: EPS: €14.40 (vs €14.43 in FY 2022)

Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591).

Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results

Full year 2023 earnings: EPS misses analyst expectations

Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million.

Virbac SA Provides Earnings Guidance for the Year 2024

Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?

Now 21% undervalued

Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up

Virbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024

Price target increased by 11% to €327

Investor sentiment improves as stock rises 15%

Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet

Virbac SA (ENXTPA:VIRP) signed an agreement to acquire Globion India Private Limited from Suguna Foods Private Limited and Lohmann Animal Health GmbH.

Virbac SA (ENXTPA:VIRP) signed an agreement to acquire Globion India Private Limited from Suguna Foods Private Limited and Lohmann Animal Health GmbH.

First half 2023 earnings released: EPS: €8.86 (vs €9.18 in 1H 2022)

Virbac SA Confirms Revenue Forecasts for the Year 2023

Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?

Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Upcoming dividend of €1.32 per share at 0.5% yield

Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?

Is Virbac (EPA:VIRP) Using Too Much Debt?

Full year 2022 earnings released: EPS: €14.44 (vs €13.40 in FY 2021)

Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?

Virbac SA to Report First Half, 2023 Results on Sep 14, 2023

Virbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023

Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate

Price target decreased to €341

Investor sentiment deteriorated over the past week

Price target decreased to €348

Virbac SA Provides Revenue Guidance for the Year 2022

Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?

First half 2022 earnings released: EPS: €9.18 (vs €8.54 in 1H 2021)

Investor sentiment deteriorated over the past week

An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued

These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely

Upcoming dividend of €1.25 per share

Full year 2021 earnings: EPS exceeds analyst expectations

Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate

We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease

Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate

Virbac SA Provides Revenue Guidance for the Year 2022

Price target increased to €435

Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock

Price target increased to €416

A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Is Virbac (EPA:VIRP) Using Too Much Debt?

Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Price target increased to €367

Virbac SA (ENXTPA:VIRP) acquired an additional 15% stake in Centrovet group for $17.7 million.

Price target increased to €341

Is Virbac SA (EPA:VIRP) Trading At A 22% Discount?

Consensus EPS estimates increase to €10.34

Price target increased to €305

Virbac SA Raises Revenue Guidance for 2021

Is Now The Time To Put Virbac (EPA:VIRP) On Your Watchlist?

Upcoming dividend of €0.75 per share

Is Virbac (EPA:VIRP) A Risky Investment?

Friulchem S.p.A. (BIT:FCM) signed a preliminary agreement to acquire Business Unit of Virbac SA (ENXTPA:VIRP) for €2.5 million.

Price target increased to €263

Consensus EPS estimates increase to €8.18

Investor sentiment improved over the past week

Virbac SA Revises Earnings Guidance for the Year 2021

Robust Earnings May Not Tell The Whole Story For Virbac (EPA:VIRP)

Full year 2020 earnings released: EPS €16.29 (vs €6.11 in FY 2019)

Desglose de ingresos y gastos
Beta